World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.

Abstract	The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.
Authors	M Boers, P Tugwell, D T Felson, P L van Riel, J R Kirwan, J P Edmonds, J S Smolen, N Khaltaev, K D Muirden
Journal	The Journal of rheumatology. Supplement (J Rheumatol Suppl) Vol. 41 Pg. 86-9 (Sep 1994) ISSN: 0380-0903 [Print] Canada
PMID	7799394 (Publication Type: Journal Article)
Chemical References	Antirheumatic Agents
Topics	Antirheumatic Agents (therapeutic use) Arthritis, Rheumatoid (complications, drug therapy) Clinical Trials as Topic Humans Rheumatology Severity of Illness Index Societies, Medical Treatment Outcome World Health Organization

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!